Cargando…
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
Autores principales: | Barzegar, Mahdi, Mirmosayyeb, Omid, Nehzat, Nasim, Sarrafi, Reza, Khorvash, Farzin, Maghzi, Amir-Hadi, Shaygannejad, Vahid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217655/ https://www.ncbi.nlm.nih.gov/pubmed/32371550 http://dx.doi.org/10.1212/NXI.0000000000000753 |
Ejemplares similares
-
Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2020) -
COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review
por: Barzegar, Mahdi, et al.
Publicado: (2021) -
Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Nehzat, Nasim, et al.
Publicado: (2021) -
Characteristics of COVID-19 disease in multiple sclerosis patients
por: Barzegar, Mahdi, et al.
Publicado: (2020) -
Association of helicobacter pylori with multiple sclerosis: Protective or risk factor?
por: Mirmosayyeb, Omid, et al.
Publicado: (2020)